3/23
08:32 am
nams
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
Medium
Report
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
3/23
08:00 am
nams
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
Medium
Report
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
3/18
04:00 pm
nams
NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
3/6
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/25
08:00 am
nams
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Medium
Report
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
2/23
06:23 am
nams
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
Low
Report
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
2/21
02:04 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at
Wall Str
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at
Wall Str
2/20
07:27 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
2/19
03:08 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/19
08:42 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/18
12:54 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $46.00 to $48.00. They now have a "buy" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $46.00 to $48.00. They now have a "buy" rating on the stock.
2/18
07:00 am
nams
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
2/6
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:00 am
nams
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
Low
Report
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
1/21
07:17 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/13
06:33 am
nams
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
1/9
08:00 am
nams
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
Medium
Report
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
1/6
07:17 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
1/5
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)